User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

The multiple pathways of endocannabinoid metabolism: a zoom out.

  1. Devane, Science, 258, 1946 (1992)
  2. Pertwee, Prog. Neurobiol., 63, 569 (2001)
  3. Rice, Prostaglandins Leukot. Essent. Fatty Acids, 66, 243 (2002)
  4. Guindon, Eur. J. Pharmacol., 550, 68 (2006)
  5. Akerman, J. Pharmacol. Exp. Ther., 309, 56 (2004)
  6. Kathuria, Nat. Med., 9, 76 (2003)
  7. Rutkowska, Pharmacol. Rep., 58, 200 (2006)
  8. Sarker, FEBS Lett., 472, 39 (2000)
  9. Mimeault, Prostate, 56, 1 (2003)
  10. Melck, FEBS Lett., 463, 235 (1999)
  11. Fowler, Biochem. Pharmacol., 66, 757 (2003)
  12. Patsos, Gut, 54, 1741 (2005)
  13. Laezza, FEBS Lett., 580, 6076 (2006)
  14. Helliwell, J. Clin. Endocrinol. Metab., 89, 5168 (2004)
  15. Habayeb, J. Clin. Endocrinol. Metab., 89, 5482 (2004)
  16. Habayeb, Life Sci., 70, 1963 (2002)
  17. Castellano, Behav. Pharmacol., 8, 707 (1997)
  18. Mallet, Psychopharmacology, 140, 11 (1998)
  19. Barros, Brain Res., 1016, 66 (2004)
  20. Varvel, J. Pharmacol. Exp. Ther., 317, 251 (2006)
  21. Kirkham, Behav. Pharmacol., 16, 297 (2005)
  22. Mechoulam R, Berry E M, Avraham Y, Di Marzo V, Fride E, Endocannabinoids, feeding and suckling – from our perspective, 10.1038/sj.ijo.0803274
  23. Matias I, Bisogno T, Di Marzo V, Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake, 10.1038/sj.ijo.0803271
  24. Mackie, Mol. Pharmacol., 44, 498 (1993)
  25. Vogel, J. Neurochem., 61, 352 (1993)
  26. Matias, Prostaglandins Leukot. Essent. Fatty Acids, 75, 413 (2006)
  27. Felder, FEBS Lett., 393, 231 (1996)
  28. Giuffrida, FEBS Lett., 422, 373 (1998)
  29. Smart, Br. J. Pharmacol., 129, 227 (2000)
  30. Al-Hayani, Neuropharmacology, 41, 1000 (2001)
  31. Caterina, Nature, 398, 436 (1999)
  32. Gunthorpe, Trends Pharmacol. Sci., 23, 183 (2002)
  33. Garcia, Naunyn Schmiedebergs Arch. Pharmacol., 368, 270 (2003)
  34. Wang, Hypertension, 46, 986 (2005)
  35. Mechoulam, Biochem. Pharmacol., 50, 83 (1995)
  36. Sugiura, Biochem. Biophys. Res. Commun., 215, 89 (1995)
  37. Stella, Nature, 388, 773 (1997)
  38. Savinainen, Br. J. Pharmacol., 134, 664 (2001)
  39. Gonsiorek, Mol. Pharmacol., 57, 1045 (2000)
  40. Sugiura, J. Biol. Chem., 275, 605 (2000)
  41. Panikashvili, Nature, 413, 527 (2001)
  42. Panikashvili, Neurobiol. Dis., 22, 257 (2006)
  43. Lepicier, Br. J. Pharmacol., 139, 805 (2003)
  44. Wagner, J. Cardiovasc. Pharmacol., 47, 650 (2006)
  45. Melck, Endocrinology, 141, 118 (2000)
  46. Nithipatikom, Cancer Res., 64, 8826 (2004)
  47. Porter, J. Pharmacol. Exp. Ther., 301, 1020 (2002)
  48. Bisogno, Biochem. J., 351, 817 (2000)
  49. Huang, Proc. Natl. Acad. Sci. U.S.A., 99, 8400 (2002)
  50. Toth, Life Sci., 73, 487 (2003)
  51. O'Sullivan, Br. J. Pharmacol., 141, 803 (2004)
  52. O'Sullivan, Eur. J. Pharmacol., 507, 211 (2005)
  53. Huang, J. Neurophysiol., 95, 1207 (2006)
  54. Sancho R., de la Vega L., Macho A., Appendino G., Di Marzo V., Munoz E., Mechanisms of HIV-1 Inhibition by the Lipid Mediator N-Arachidonoyldopamine, 10.4049/jimmunol.175.6.3990
  55. Saghatelian, Biochemistry, 43, 14332 (2004)
  56. Saghatelian, Biochemistry, 45, 9007 (2006)
  57. Bachur, J. Biol. Chem., 240, 1019 (1965)
  58. Kondo, Arch. Biochem. Biophys., 354, 303 (1998)
  59. Calignano, Nature, 394, 277 (1998)
  60. Baker, FASEB J., 15, 300 (2001)
  61. Epps, Biochem. Biophys. Res. Commun., 90, 628 (1979)
  62. Lambert, Epilepsia, 42, 321 (2001)
  63. Petrocellis, Fundam. Clin. Pharmacol., 16, 297 (2002)
  64. Conti, Br. J. Pharmacol., 135, 181 (2002)
  65. Lambert Didier, Vandevoorde Severine, Jonsson Kent-Olov, Fowler Christopher, The Palmitoylethanolamide Family: A New Class of Anti-Inflammatory Agents ?, 10.2174/0929867023370707
  66. LoVerme, Mol. Pharmacol., 67, 15 (2005)
  67. LoVerme, Life Sci., 77, 1685 (2005)
  68. Tan, Am. Assoc. Pharm. Sci. J., 8 (2006)
  69. Cravatt, Nature, 384, 83 (1996)
  70. Giang, Proc. Natl. Acad. Sci. U.S.A., 94, 2238 (1997)
  71. Bracey, Science, 298, 1793 (2002)
  72. Dinh, Proc. Natl. Acad. Sci. U.S.A., 99, 10819 (2002)
  73. Ueda, J. Biol. Chem., 276, 35552 (2001)
  74. Tsuboi, Biochem. J., 379, 99 (2004)
  75. Tsuboi, J. Biol. Chem., 280, 11082 (2005)
  76. Fowler, Biochem. Pharmacol., 69, 1241 (2005)
  77. Kozak, Curr. Pharm. Des., 10, 659 (2004)
  78. Stelt, Eur. J. Biochem., 267, 2000 (2000)
  79. Kozak, J. Biol. Chem., 277, 23278 (2002)
  80. Deutsch, Biochem. Pharmacol., 46, 791 (1993)
  81. Desarnaud, J. Biol. Chem., 270, 6030 (1995)
  82. Ueda, J. Biol. Chem., 270, 23823 (1995)
  83. Goparaju, Biochem. Pharmacol., 57, 417 (1999)
  84. Ueda, Prostaglandins Other Lipid Mediat., 61, 19 (2000)
  85. Ueda, Chem. Phys. Lipids, 108, 107 (2000)
  86. Patricelli, J. Biol. Chem., 2 (2000)
  87. McKinney, J. Biol. Chem., 278, 37393 (2003)
  88. Mor, J. Med. Chem., 47, 4998 (2004)
  89. Basso, J. Mass Spectrom., 39, 1450 (2004)
  90. Alexander, Chem. Biol., 12, 1179 (2005)
  91. Pertwee, Am. Assoc. Pharm. Sci. J., 7 (2005)
  92. Fowler, Brain Res. Rev., 41, 26 (2003)
  93. Fowler, Pharmacol. Biochem. Behav., 81, 248 (2005)
  94. Lambert, J. Med. Chem., 48, 5059 (2005)
  95. Jonsson, Basic Clin. Pharmacol. Toxicol., 98, 124 (2006)
  96. Park, Placenta, 24, 473 (2003)
  97. Erratum, Placenta, 24, 990 (2003)
  98. Katayama Kazuhisa, Ueda Natsuo, Kurahashi Yuko, Suzuki Hiroshi, Yamamoto Shozo, Kato Itsuo, Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine, 10.1016/s0005-2760(97)00078-7
  99. Bisogno, Arch. Biochem. Biophys., 370, 300 (1999)
  100. Yazulla, J. Comp. Neurol., 415, 80 (1999)
  101. Matsuda, Exp. Eye Res., 64, 707 (1997)
  102. Glaser, Vis. Neurosci., 22, 693 (2005)
  103. Hillard Cecilia J., Wilkison Douglas M., Edgemond William S., Campbell William B., Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain, 10.1016/0005-2760(95)00087-s
  104. Paria, Mol. Reprod. Dev., 45, 183 (1996)
  105. Paria, Biol. Reprod., 60, 1151 (1999)
  106. Wang, J. Clin. Invest., 116, 2122 (2006)
  107. Maurelli, FEBS Lett., 377, 82 (1995)
  108. Bisogno, J. Biol. Chem., 272, 3315 (1997)
  109. Jacobsson, Br. J. Pharmacol., 132, 1743 (2001)
  110. Matias, Eur. J. Biochem., 269, 3771 (2002)
  111. Aguado, J. Neurosci., 26, 1551 (2006)
  112. Siegmund, J. Biol. Chem., 281, 10431 (2006)
  113. Omeir, Biochem. Biophys. Res. Commun., 264, 316 (1999)
  114. Schmid, J. Biol. Chem., 260, 14145 (1985)
  115. Egertová, Neuroscience, 119, 481 (2003)
  116. Patricelli, Biochemistry, 38, 14125 (1999)
  117. McKinney, Biochemistry, 45, 9016 (2006)
  118. Cravatt, Proc. Natl. Acad. Sci. U.S.A., 98, 9371 (2001)
  119. Lichtman, Pain, 109, 319 (2004)
  120. Clement, J. Neurosci., 23, 3916 (2003)
  121. Pacher, Am. J. Physiol. Heart Circ. Physiol., 289 (2005)
  122. Basavarajappa, Neuropharmacology, 50, 834 (2006)
  123. Huitron-Resendiz, Sleep, 27, 857 (2004)
  124. Mulder, Biochemistry, 45, 11267 (2006)
  125. Cupini, Cephalalgia, 26, 277 (2006)
  126. Bluher, Diabetes, 55, 3053 (2006)
  127. Steffens, Neurosci. Lett., 385, 13 (2005)
  128. Wei, J. Biol. Chem., 281, 36569 (2006)
  129. Tornqvist, J. Biol. Chem., 251, 813 (1976)
  130. Karlsson, J. Biol. Chem., 272, 27218 (1997)
  131. Lichtman, J. Pharmacol. Exp. Ther., 302, 73 (2002)
  132. Karlsson, Gene, 272, 11 (2001)
  133. Vandevoorde, Curr. Pharm. Des., 11, 2647 (2005)
  134. Gulyas, Eur. J. Neurosci., 20, 441 (2004)
  135. Saario, Biochem. Pharmacol., 67, 1381 (2004)
  136. Vandevoorde, Biochem. Biophys. Res. Commun., 337, 104 (2005)
  137. Saario, Chem. Biol., 12, 649 (2005)
  138. Saario, Chem. Biol., 13, 811 (2006)
  139. Vandevoorde, Br. J. Pharmacol., 150, 186 (2007)
  140. N. Stella, 16th Annual Symposium on the Cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, 2006, p. 20.
  141. Ueda, FEBS Lett., 454, 267 (1999)
  142. Sun Yong-Xin, Tsuboi Kazuhito, Zhao Li-Ying, Okamoto Yasuo, Lambert Didier M., Ueda Natsuo, Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages, 10.1016/j.bbalip.2005.08.010
  143. O'Neill, FEBS Lett., 330, 156 (1993)
  144. Hinz, J. Pharmacol. Exp. Ther., 300, 367 (2002)
  145. Nogawa, J. Neurosci., 17, 2746 (1997)
  146. Resnick, J. Neurotrauma, 15, 1005 (1998)
  147. Yasojima K., Tourtellotte W. W., McGeer E. G., McGeer P. L., Marked increase in cyclooxygenase-2 in ALS spinal cord: Implications for therapy, 10.1212/wnl.57.6.952
  148. Cernak, Clin. Exp. Pharmacol. Physiol., 28, 922 (2001)
  149. Minghetti L., Cardone F., Greco A., Puopolo M., Levi G., Green A. J.E., Knight R., Pocchiari M., Increased CSF levels of prostaglandin E2 in variant Creutzfeldt-Jakob disease, 10.1212/wnl.58.1.127
  150. Bazan, Prostaglandins Other Lipid Mediat., 68–69, 197 (2002)
  151. Teismann, Ann. N.Y. Acad. Sci., 991, 272 (2003)
  152. Prescott, Biochim. Biophys. Acta, 1470 (2000)
  153. Mizuno, Gastroenterology, 112, 387 (1997)
  154. Fu, Gastroenterology, 116, 1319 (1999)
  155. DeWitt, Proc. Natl. Acad. Sci. U.S.A., 85, 1412 (1988)
  156. Yokoyama, Biochem. Biophys. Res. Commun., 165, 888 (1989)
  157. Järving, J. Biol. Chem., 279, 13624 (2004)
  158. Picot, Nature, 367, 243 (1994)
  159. Luong, Nat. Struct. Biol., 3, 927 (1996)
  160. Kurumbail, Nature, 384, 644 (1996)
  161. Erratum, Nature, 385, 555 (1997)
  162. Bayly, Bioorg. Med. Chem. Lett., 9, 307 (1999)
  163. Simmons, Pharmacol. Rev., 56, 387 (2004)
  164. Snipes, J. Pharmacol. Exp. Ther., 313, 668 (2005)
  165. Kis, J. Pharmacol. Exp. Ther., 315, 1 (2005)
  166. Smith, Prostaglandins Other Lipid Mediat., 68–69, 115 (2002)
  167. Lands W.E.M., Samuelsson B., Phospholipid precursors of prostaglandins, 10.1016/0005-2760(68)90168-9
  168. Vonkeman H., Van Dorp D.A., The action of prostaglandin synthetase on 2-arachidonyl-lecithin, 10.1016/0005-2760(68)90169-0
  169. Yu, J. Biol. Chem., 272, 21181 (1997)
  170. Kozak, J. Biol. Chem., 275, 33744 (2000)
  171. Kozak, J. Biol. Chem., 277, 44877 (2002)
  172. Coffey, Proc. Natl. Acad. Sci. U.S.A., 94, 657 (1997)
  173. Weber, J. Lipid Res., 45, 757 (2004)
  174. Kozak, Biochemistry, 42, 9041 (2003)
  175. Kozak, J. Biol. Chem., 276, 30072 (2001)
  176. Matias, J. Pharmacol. Exp. Ther., 309, 745 (2004)
  177. Nirodi, Proc. Natl. Acad. Sci. U.S.A., 101, 1840 (2004)
  178. Sang Nan, Zhang Jian, Chen Chu, PGE2glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons : Novel prostanoids in synaptic signalling, 10.1113/jphysiol.2006.105569
  179. Rockwell, J. Pharmacol. Exp. Ther., 311, 683 (2004)
  180. Dinchuk, Nature, 378, 406 (1995)
  181. Morham, Cell, 83, 473 (1995)
  182. Langenbach, Cell, 83, 483 (1995)
  183. Iadecola, J. Cereb. Blood Flow Metab., 21, 1436 (2001)
  184. Bonner James C., Rice Annette B., Ingram Jennifer L., Moomaw Cindy R., Nyska Abraham, Bradbury Alyce, Sessoms Alisha R., Chulada Patricia C., Morgan Daniel L., Zeldin Darryl C., Langenbach Robert, Susceptibility of Cyclooxygenase-2-Deficient Mice to Pulmonary Fibrogenesis, 10.1016/s0002-9440(10)64202-2
  185. Houchen, Am. J. Physiol. Grastroinvest. Liver Physiol., 279 (2000)
  186. Schmassmann, Am. J. Physiol. Grastroinvest. Liver Physiol., 290 (2006)
  187. Camitta, Circulation, 104, 2453 (2001)
  188. Chillingworth N. L., Sex differences in inflammation and inflammatory pain in cyclooxygenase-deficient mice, 10.1152/ajpregu.00901.2005
  189. Carey M. A., Bradbury J. A., Seubert J. M., Langenbach R., Zeldin D. C., Germolec D. R., Contrasting Effects of Cyclooxygenase-1 (COX-1) and COX-2 Deficiency on the Host Response to Influenza A Viral Infection, 10.4049/jimmunol.175.10.6878
  190. Iadecola, Proc. Natl. Acad. Sci. U.S.A., 98, 1294 (2001)
  191. Wormser, Toxicol. Appl. Pharmacol., 200, 40 (2004)
  192. Myers, Arthritis Rheum., 43, 2687 (2000)
  193. Langenbach, Ann. N.Y. Acad. Sci., 889, 52 (1999)
  194. Loftin, Prostaglandins Other Lipid Mediat., 68–69, 177 (2002)
  195. Prigge, Biochimie, 79, 629 (1997)
  196. Sigal, J. Biol. Chem., 263, 5328 (1988)
  197. Yoshimoto, Prostaglandins Other Lipid Mediat., 68–69, 245 (2002)
  198. Boyington, Science, 260, 1482 (1993)
  199. Glickman, Biochemistry, 35, 12882 (1996)
  200. Zhang, Proc. Natl. Acad. Sci. U.S.A., 89, 485 (1992)
  201. Kühn Hartmut, Borngräber Sabine, Mammalian 15-Lipoxygenases, Advances in Experimental Medicine and Biology (1999) ISBN:9780306460449 p.5-28, 10.1007/978-1-4615-4861-4_2
  202. Brash, J. Biol. Chem., 274, 23679 (1999)
  203. Catalano, Histol. Histopathol., 20, 969 (2005)
  204. Mehrabian, Curr. Opin. Lipidol., 14, 447 (2003)
  205. Jakobsson, Proc. Natl. Acad. Sci. U.S.A., 89, 3521 (1992)
  206. Zadelhoff, Biochem. Biophys. Res. Commun., 248, 33 (1998)
  207. Moody, Biochemistry, 40, 861 (2001)
  208. Goulet, Proc. Natl. Acad. Sci. U.S.A., 91, 12852 (1994)
  209. Chen, Nature, 372, 179 (1994)
  210. Chen, J. Neuroimmunol., 120, 94 (2001)
  211. Bailie, J. Immunol., 157, 5221 (1996)
  212. Goulet J. L., Griffiths R. C., Ruiz P., Mannon R. B., Flannery P., Platt J. L., Koller B. H., Coffman T. M., Deficiency of 5-Lipoxygenase Accelerates Renal Allograft Rejection in Mice, 10.4049/jimmunol.167.11.6631
  213. Cuzzocrea, J. Leukocyte Biol., 73, 739 (2003)
  214. Patel, Mol. Pharmacol., 66, 220 (2004)
  215. Sun, J. Biol. Chem., 271, 24055 (1996)
  216. Vahsen, Horm. Metab. Res., 38, 391 (2006)
  217. Bleich, J. Clin. Invest., 103, 1431 (1999)
  218. Reddy, Hypertension, 41, 1294 (2003)
  219. Gabel, Am. J. Physiol. Heart Circ. Physiol., 280 (2001)
  220. Walters, Psychopharmacology, 170, 124 (2003)
  221. Lichtman, J. Pharmacol. Exp. Ther., 311, 441 (2004)
  222. Wiley, Life Sci., 80, 24 (2006)
Bibliographic reference Vandevoorde, Severine ; Lambert, Didier M. The multiple pathways of endocannabinoid metabolism: a zoom out.. In: Chemistry & biodiversity, Vol. 4, no. 8, p. 1858-81 (2007)
Permanent URL http://hdl.handle.net/2078.1/29439